Hidradenitis suppurativa treated with combination of infliximab and dapsone

Bratislava Medical Journal

Volumn 113, Issue 5, 2012, Pages 319-323

  Kozub, P ^a   Simaljakova, M ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Dapson; Hidradenitis suppurativa; Infliximab; Sulphonates; Therapy; TNF inhibitors

Indexed keywords

DAPSONE; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CASE REPORT; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MIDDLE AGED; SUPPURATIVE HIDRADENITIS;

ANTIBODIES, MONOCLONAL; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871814321     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2012_074     Document Type: Article

References (19)

1. Naldi L. Epidemiology. In: Jemec G, Revuz J, Leyden J (Eds). Hidradenitis suppurativa, Vol.1, Springer, 2006, 58-64.
2. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNFa therapies. J Cutan Med Surg 2005; 9: 296-302.
3. Martinez F, Nos P, Benlloch S et al. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7 (4): 323-326.
4. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002; 97: 2155-2156.
5. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49: S275-276.
6. Adams DR, Gordon KB, Devenyi AG et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-1542.
7. Sullivan TP, Welsh E, Kerdel FA et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-1049.
8. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2007; 158: 370-374.
9. Thielen AM, Barde C, Saurat J-H. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 154: 1105-1108.
10. Brunasso AMG, Delfino C, Massone C. Hidradenitis suppurativa: are tumor necrosis factor-a blockers the ultimate alternative? Br J Dermatol 2008; 159: 761-763.
11. Grant A, Gonzales T, Montgomery MO et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2009; 62 (2): 205-217.
12. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002; 47: 280-285.
13. Kaur MR, Gupta S, Taibjee S, Lewis HM. Hidradenitis suppurativa treated with dapsone, a case series of six patients. Br J Dermatol 2005; 153 (Suppl 1): 39-40.
14. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatol Treat 2006; 17 (4): 211-213.
15. Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-1112.
16. Pelekanou A, Kanni T, Savva A et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol 2010; 19: 538-540.
17. Cusack C, Buckley C. Etanercept: effective in management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-729.
18. Zangrilli A, Esposito M, Mio G, Mazzotta A, Chimenti S. Longterm efficacy of etanercept in hidradenitis suppurativa. JEADV 2008; 22: 1260-1262.
19. van der Zee HH, van der Wounde CI, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162: 195-197.